meta
|
evidence
COVID-19
Living systematic review and meta-analysis
anti-inflammatory therapies
adjuvant therapies
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
anti GM-CSF
mavrilimumab
Namilumab
otilimab
clarithromycine
colchicine
Colchicine plus rosuvastatin
mepolizumab
naproxen, ibuprofen
non-steroidal anti-inflammatory drugs
Celecoxib
Ibuprofen
Indomethacin
selinexor
sodium aescinate
stem cells
tradipitant
vilobelimab (IFX-1)
Apilimod
corticosteroids
Immunostimulants drugs
Immunosuppressants drugs
inhaled corticosteroids
Kinase inhibitors
leflunomide
meplazumab
pirfenidone
Polyinosinic-Polycytidylic Acid
sargramostim
statins
thymosin
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
Filter by comparators...
potential COVID-19 treatments
adjuvant therapies
paracetamol
antiviral and associated therapy
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine
control
placebo
standard of care
COVID 19 hospitalized
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
patient subgroup...
non invasive oxygen
patient subgroup...
non invasive oxygen
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded